New targeted treatments in lung cancer — overview of clinical trials
- 31 August 2004
- journal article
- review article
- Published by Elsevier in Lung Cancer
- Vol. 45, S199-S208
- https://doi.org/10.1016/j.lungcan.2004.07.974
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence In Situ Hybridization : A Single-Institution Experience of 2,279 Cases and Comparison of Dual-Color and Single-Color ScoringAmerican Journal of Clinical Pathology, 2004
- Treatment of non-small-cell lung cancer: state of the art and development of new biologic agentsOncogene, 2003
- O-188 Encouraging activity and durable responses demonstrated by the epithelial growth factor receptor-tyrosine kinase inhibitor, Erlotinib (Tarceva TM, OSI774), in patients with advanced bronchioloalveolar (BAC) cell carcinomaLung Cancer, 2003
- O-112 A phase I/II study of the anti-VEGF MAb bevacizumab (Avastin™) and erlotinib (Tarceva™), a HER1/EGFR-TK inhibitor: a multi-faceted approach for the treatment of recurrent non-small cell lung cancerLung Cancer, 2003
- P-611 Final results from a phase II study of erlotinib (TarcevaTM) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapyLung Cancer, 2003
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyBlood, 2002
- Global cancer statistics in the year 2000The Lancet Oncology, 2001
- The Hallmarks of CancerCell, 2000
- Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cellsNature, 1984